Maraviroc mvc

A total of 61 WT C57BL/6J male mice were purchased from Charles River (Barcelona, Spain). All animals had unrestricted access to food and water during the study. When the animals were approximately 5 weeks old, they were randomly assigned to one of 4 diet groups: (i) Control, (ii) MVC, (iii) CDE diet and (iv) CDE + MVC. Control group mice were fed a choline-sufficient diet (MP Biomedicals, Illkirch, France, SKU 02960414-CF) and tap water, n = 10. Mice in the MVC group received the Control group diet, supplemented with 300 mg/L Maraviroc (MVC, Pfizer, New York, NY, USA) in the drinking water, n = 11. For the correct MVC dose in mice, an interspecies allometric scaling factor of 12.3 was used, resulting in a dose equivalent to a human dose of 300 mg/day [29 (link)]. The CDE-diet-treated animals received the choline-deficient diet (MP Biomedicals, SKU: 02960210-CF,), and 0.165% ethionine (Sigma, St Louis, MO, USA) supplemented the drinking water, n = 20. Finally, the CDE + MVC-treated animals were fed with the same diet as the CDE group but received MVC in the drinking water at the same concentration as the MVC group, n = 20. All surviving animals were sacrificed at week 16. Tissue pieces were fixed in buffered formalin (10%) for histological analysis or snap-frozen in liquid nitrogen for biochemical and molecular analyses.